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Continuous treatment with organic nitrates causes nitrate tolerance and endothelial dysfunction, which is involved with protein
kinaseC (PKC) signal pathway andNADPHoxidase activation.Wedeterminedwhether chronic administrationwith nitroglycerine
compromises the protective effects of propofol against tumor necrosis factor (TNF-) induced toxicity in endothelial cells by PKC-𝛽
2
dependent NADPH oxidase activation. Primary cultured human umbilical vein endothelial cells were either treated or untreated
with TNF-𝛼 (40 ng/mL) alone or in the presence of the specific PKC-𝛽
2
inhibitor CGP53353 (1𝜇M)), nitroglycerine (10𝜇M),
propofol (100𝜇M), propofol plus nitroglycerin, or CGP53353 plus nitroglycerine, respectively, for 24 hours. TNF-𝛼 increased
the levels of superoxide, Nox (nitrate and nitrite), malondialdehyde, and nitrotyrosine production, accompanied by increased
protein expression of p-PKC-𝛽
2
, gP91phox, and endothelial cell apoptosis, whereas all these changes were further enhanced
by nitroglycerine. CGP53353 and propofol, respectively, reduced TNF-𝛼 induced oxidative stress and cell toxicity. CGP53353
completely prevented TNF-𝛼 induced oxidative stress and cell toxicity in the presence or absence of nitroglycerine, while the
protective effects of propofol were neutralized by nitroglycerine. It is concluded that nitroglycerine comprises the protective effects
of propofol against TNF-𝛼 stimulation in endothelial cells, primarily through PKC-𝛽
2
dependent NADPH oxidase activation.
1. Introduction
Ischemic heart disease is a leading cause of death in many
regions. The mortality of myocardial infarction remains sig-
nificant despite advancement in surgical techniques and pha-
rmacological therapies. Organic nitrates (such as nitroglyc-
erin, L-arginine) are still useful drugs and have been widely
used for the prevention and treatment of ischemic heart dise-
ase for more than 100 years [1, 2]. However, these drugs
are also known to induce nitrate tolerance after prolonged,
continuous, or high dose administration, which leads to
the abolishment of clinical or hemodynamic response to
organic nitrates [3] and subsequently induces endothelial
dysfunction [4]. It has been reported that nitrate tolerance
and endothelial dysfunction are associated with increased
vascular production of reactive oxygen species (ROS) via
mechanisms that involve increased protein kinase C (PKC)
andNADPHoxidase activation, eNOS uncoupling in the vas-
cular endothelium [4–6]. Interestingly, circulatory proapop-
totic inflammatory cytokines (such as tumor necrosis factor
(TNF-)𝛼), which are increased during myocardial infraction
and atherosclerosis, may promote the production of ROS
subsequent to the induction of cardiomyocyte apoptosis
and endothelial cells apoptosis [7]. A further study had
shown TNF-𝛼 induced human endothelial cell apoptosis
which involved the activation of PKC [8]. Despite these
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observations, whether or not organic nitrates aggravate TNF-
𝛼 induced endothelial cell apoptosis and the underlying
mechanisms by which PKC isoforms exert adverse effects in
this pathology remain unclear.
Propofol, an anesthetic with demonstrated antioxidant
properties [9], has shown protective effects in various models
against ischemia-reperfusion injury [10–12]. We previously
reported that propofol dose-dependently reduced TNF-𝛼
induced apoptosis in primary cultured human umbilical vein
endothelial cells (HUVECs) [13]. Our further study showed
that the supplementation of L-arginine exacerbated TNF-
𝛼 induced cellular toxicity by enhancing oxidative stress
and nitrative stress, which was neutralized by propofol trea-
tment [14]. It is unknown, however, whether or not propofol
achieves these effects via inhibition of PKC-𝛽
2
, a PKC
isoform that may play a major role in TNF-𝛼 induced human
endothelial cell apoptosis [15]. Of interest, propofol has been
shown to activate PKC-𝛼, PKC-𝛿, PKC-𝜀, and PKC-𝜉 in
cardiomyocytes [16–18], which may represent an important
cellular mechanism of propofol-induced myocardial protec-
tion in the setting of ischemia-reperfusion injury. However,
in all these studies, the effect of propofol on PKC-𝛽
2
has not
been reported, nor has it been investigated in endothelial cells
in the condition of nitrate tolerance. In the present study, we
hypothesize that nitrate tolerance induced by organic nitrates
comprises the protective effects of propofol against TNF-𝛼
induced toxicity in endothelial cells. Our data suggests that
nitroglycerine supplementation promoted PKC-𝛽
2
activation
in HUVECs subjected to TNF-𝛼 stimulation, which sub-
sequently increased the activation of NADPH oxidase and
compromised the protective effects of propofol against TNF-
𝛼 induced damage.
2. Materials and Methods
2.1. Cell Culture. Primary culturedHUVECswill be prepared
using established procedures as previously described [13].
Briefly, cells were digested from the umbilical vein with 0.1%
collagenase I (w/v) at 37∘C for 20min, after which they were
cultured in 0.1% (w/v) gelatin-coated flasks in Medium 199
supplemented with 10% fetal bovine serum, 15mg/L ECGS,
2mM glutamine, 100 units/mL penicillin, and 100 𝜇g/mL
streptomycin in an atmosphere of 5% CO
2
at 37∘C. The
medium was changed every 2-3 days until the ECs reached
confluence. Cultured cells were identified as ECs by their
morphology and the presence of the Factor VIII-related anti-
gen was detected using an indirect immunocytochemistry
method as described [19]. The purity of HUVECs in culture
was higher than 95% and passages 2–4 were used in the
research.
2.2. Experimental Conditions. When the cells were at 70%
confluence, the cultured cells were then randomly divided
into the following groups: cells were either not treated (con-
trol group, Con.) or treated with 40 ng/mL TNF-𝛼 (TNF-𝛼
group, T) alone or TNF-𝛼 in the presence of 1𝜇MCGP53353
(CGP) (TNF-𝛼 + CGP group, T + C), 10 𝜇M nitroglycerine
(NTG) (TNF-𝛼 + NTG group, T + N), 100 𝜇M propofol
(TNF-𝛼 + propofol group, T + P), or NTG plus propofol
(TNF-𝛼 + NTG + propofol group, T + N + P), and NTG
plus CGP53353 (TNF-𝛼 + NTG + CGP53353 group, T + N +
C), respectively, for 24 hours. In specific groups, cultured
cells were pretreated with propofol for 30min before other
treatments. The concentration of TNF-𝛼 used to induce
apoptosis in the present study was chosen on the basis of our
previous studies [13], which demonstrated that TNF-𝛼 at the
dose of 40 ng/mL could significantly induce ECs apoptosis.
The concentration ofNTG adopted is according to the studies
[20, 21], which demonstrated that NTG at the dose of 10𝜇M
could induce nitrate tolerance. The choice of concentration
of PKC-𝛽
2
inhibitor was based on that 1 𝜇MCGP53353 could
selectively inhibit PKC-𝛽
2
activation in our previous study
[22]. In our preliminary study, propofol at the dose of 100 𝜇M
reversed TNF-𝛼 (40 ng/mL) induced cell injury but propofol
at the dose of 100 𝜇Mper se did not cause apparent apoptosis
under the present experimental condition in the absence of
TNF-𝛼 stimulation. Therefore, we chose the concentration
of 100 𝜇M as the treatment dose of propofol for the further
mechanistic study.
2.3. Determination of Cytotoxicity. Cytotoxicity will be asse-
ssed by measuring lactate dehydrogenase (LDH) (Jiancheng
Co., Nanjing, China) release in the medium in addition to
the measurement of cell viability using the 3-(4,5-Dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma, St. Louis, MO, USA) assay according to the manufa-
cturer’s instructions.
2.4. Determination of Lipid Peroxidation. The content ofmal-
ondialdehyde (MDA), which is a marker of lipid peroxida-
tion, was measured to evaluate the oxidative injury of ECs.
After homogenizing on ice in normal saline, the MDA levels
of the supernatants of cell samples was determined by the
thiobarbituric acid colorimetricmethod usingMDA assay kit
(Jiancheng Co., Nanjing, China) as described [23, 24]. The
results were expressed as nanomole per milligram protein
(nmol/mg protein).
2.5. Determination of the Levels of NOx, O
2
−, and Nitroty-
rosine. Cultured cells were homogenized in ice-cold PBS
and centrifuged at 3,000 g for 15 minutes at 4∘C for super-
natant collection.The supernatant protein concentration was
determined via a Lowry assay kit (Bio-Rad, CA, USA).
Concentrations of nitrites (NO
2
−) and nitrates (NO
3
−),
the stable end products of nitric oxide (NO), were deter-
mined by the Griess reaction as previously described [13].
NOx levels were expressed as 𝜇mol/L protein. Myocardial
O
2
− production was determined via lucigenin chemilumi-
nescence method [25, 26]. The supernatant samples were
loaded with dark-adapted lucigenin (5𝜇M) and read in 96-
well microplates by luminometer (GloMax, Promega). Light
emission, expressed as mean light units (MLU)/min/100 𝜇g
protein, was recorded for 5minutes.Myocardial nitrotyrosine
levels (𝜇g/mg protein) in the collected supernatant were
determined by chemiluminescence detection via the Nitroty-
rosine Assay Kit per manufacturer’s protocol (Millipore,
USA).
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Figure 1: Cell viability (a) and LDH release (b). Primary cultured human umbilical vein endothelial cells (HUVECs) were either not treated
(control, Con.) or treated with TNF-𝛼 (40 ng/mL) alone (T) or with TNF-𝛼 in the presence of nitroglycerine (10 𝜇M) (T + N), propofol
(100𝜇M) (T+P), CGP53353 (1𝜇M) (T+C), propofol plus nitroglycerin (T+N+P), orCGP53353 plus nitroglycerine (T+N+C), respectively,
for 24 h. All results are expressed as mean ± S.E.M., 𝑛 = 7, ∗𝑃 < 0.05 compared with Con., T + N, T + P, T + C and T + N + C, ∗∗𝑃 < 0.01
compared with Con., T + P, T + C and T + N + C.
2.6. Detection of Apoptosis by Flow Cytometry. DNA frag-
ments which are lost from apoptotic nuclei and nuclear
DNA content can be easily measured by flow cytometry after
nucleic acid stainingwith specific fluorochromes. Briefly, cells
(1 × 106) were harvested and processed as described [14].
Then the cells were performed to Annexin-V-fluos Staining
and analyzed using a flow cytometer (Beckman Coulter,
Brea, CA) according to manufacturer’s protocol. Electronic
compensation of the instrument is required to exclude over-
lapping of the two emission spectra. All measurements were
performed in the same instrumental settings.
2.7. Western Blot Analysis. Cultured cells were homogenized
in cell lysis buffer containing Tris-HCl (20mM, pH 7.4),
NaCl (150mM), EDTA (lmM), EGTA (lmM), 𝛽-glyce-
rolphosphate (1mM), sodium pyrophosphate (2.5mM), Tri-
ton X-100 (1%), PMSF (1mM), DTT (l mM), leupeptin
(1 𝜇g/mL), aprotinin (1 𝜇g/mL), and pepstatin (1 𝜇g/mL).The
homogenate was centrifuged at 1,000 g for 10min at 4∘C to
collect the supernatant as total protein preparations. Equal
amounts of protein were combined with 5×SDS loading
buffer, boiled for 5min, then separated via 10% SDS-PAGE,
and subsequently transferred to PVDFmembrane for immu-
noblot analysis. The membranes were blocked in 5% no
fat milk for 2 hours at room temperature and then incu-
bated overnight at 4∘C with primary antibodies against
p-PKC-𝛽
2
(ser660) (1 : 1000, Cell Signaling Technology),
PKC-𝛽2 (1 : 1000, Cell Signaling Technology), and gP91phox
(1 : 500, Santa Cruz Biotechnology). After being washed with
TBST, the membranes were incubated with proper seco-
ndary horseradish peroxidase (HRP-)conjugated antibodies
(1 : 5,000–1 : 10,000, Cell Signaling Technology) and devel-
opedwith enhanced chemiluminescence reagent (GEHealth-
care, USA). The membranes were subsequently reblotted
for GAPDH (1 : 2,000, Cell Signaling Technology), and the
results were normalized to GAPDH to correct for loading.
2.8. Statistical Analysis. All the data are expressed as mean ±
S.E.M. Significance was evaluated by analysis of one-way
variance (ANOVA) followed by Tukey’s test. GraphPad Prism
software program (GraphPad Software Inc., San Diego, CA,
USA) was used for statistical analysis. 𝑃 < 0.05 was conside-
red statistically significant.
3. Results
3.1. Cell Viability and LDH Release. The cytotoxicity of the
cultured endothelial cells was assessed by MTT assay and
LDH release. As shown in Figure 1(a), cell viability was
significantly reduced after TNF-𝛼 stimulation as compared
with control, which was reversed by propofol treatment.
The supplementation of nitroglycerine further exacerbated
TNF-𝛼 induced reduction in cell viability. The treatment
of propofol improved but not restored the viability of the
cells subjected to TNF-𝛼 stimulation in the presence of
nitroglycerine. By contrast, CGP53353, a selective inhibitor of
PKC-𝛽
2
, reversed the reduced cell viability induced byTNF-𝛼
with or without the presence of nitroglycerine.
Stimulation with TNF-𝛼 resulted in a significant increase
in LDH release in the medium of cultured HUVECs
(Figure 1(b)). Addition of nitroglycerine further increased
TNF-𝛼 induced LDH release. Both propofol and CGP53353
significantly restored the TNF-𝛼 induced LDH release. By
contrast, propofol reduced but not reversed the levels of LDH
release in the presence of nitroglycerine.
3.2. Endothelial Cell Apoptosis. Stimulation of HUVECs with
TNF-𝛼 resulted in a marked significant increase in apoptotic
4 Oxidative Medicine and Cellular Longevity
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Figure 2: Representative figures of flow cytometry results (a)–(g) and rate of apoptotic cells measured by flow cytometry (h). Flow cytometric
analysis was carried out as described inmethods. Primary cultured human umbilical vein endothelial cells (HUVECs) were either not treated
(control, Con.) or treated with TNF-𝛼 (40 ng/mL) alone (T) or with TNF-𝛼 in the presence of nitroglycerine (10 𝜇M) (T + N), propofol
(100𝜇M) (T+P), CGP53353 (1𝜇M) (T+C), propofol plus nitroglycerin (T+N+P), orCGP53353 plus nitroglycerine (T+N+C), respectively,
for 24 h. (a)–(g) Representatives of the C, T, T + N, T + P, T + N + P, T + C and T + N + C, respectively. All results are expressed as mean ±
S.E.M., 𝑛 = 7, ∗𝑃 < 0.05 compared with Con., T + N, T + P, T + C and T + N + C, ∗∗𝑃 < 0.01 compared with Con., T + P, T + C and T + N +
C.
index (Figure 2). Nitroglycerine further increased TNF-𝛼
induced cell apoptotic death. On the other hand, CGP53353
and propofol significantly attenuated cell apoptosis induced
by TNF-𝛼. Propofol attenuated but not prevented the com-
bination of nitroglycerine and TNF-𝛼 induced cell apoptotic
death, which was profoundly decreased by the treatment of
CGP53353. The patterns of apoptotic index results obtained
from TUNEL staining were similar to those obtained by flow
cytometry (data not shown).
3.3. Superoxide and MDA Production. As the production
of ROS plays an important role in the development and
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Figure 3: Effects of TNF-𝛼, nitroglycerine, and CGP53353 on MDA (a) and superoxide production (b). Primary cultured human umbilical
vein endothelial cells (HUVECs) were either not treated (control, Con.) or treated with TNF-𝛼 (40 ng/mL) alone (T) or with TNF-𝛼 in the
presence of nitroglycerine (10𝜇M) (T + N), propofol (100𝜇M) (T + P), CGP53353 (1 𝜇M) (T + C), propofol plus nitroglycerin (T + N + P),
or CGP53353 plus nitroglycerine (T + N + C), respectively, for 24 h. All results are expressed as mean ± S.E.M., 𝑛 = 7, ∗𝑃 < 0.05 compared
with Con., T + N, T + P, T + C and T + N + C, ∗∗𝑃 < 0.01 compared with Con., T + P, T + C and T + N + C.
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Figure 4: Effects of TNF-𝛼, nitroglycerine and CGP53353 on NOx (a) and nitrotyrosine production (b). Primary cultured human umbilical
vein endothelial cells (HUVECs) were either not treated (control, Con.) or treated with TNF-𝛼 (40 ng/mL) alone (T) or with TNF-𝛼 in the
presence of nitroglycerine (10𝜇M) (T + N), propofol (100𝜇M) (T + P), CGP53353 (1𝜇M) (T + C), propofol plus nitroglycerin (T + N + P), or
CGP53353 plus nitroglycerine (T + N + C), respectively, for 24 h. All results are expressed as mean ± S.E.M., 𝑛 = 7, (a) ∗𝑃 < 0.05 compared
with Con., T + N, T + P, T + N + P and T + C, ∗∗𝑃 < 0.01 compared with T + N, T + P and T + N + P; (b) ∗𝑃 < 0.05 compared with Con., T
+ N, T + P, T + C and T + N + C, ∗∗𝑃 < 0.01 compared with Con., T + P, T + C and T + N + C.
progress of nitrate tolerance and endothelial dysfunction [4],
we measured superoxide and MDA production, which is
a marker of lipid peroxidation. As shown in Figure 3, the
levels of superoxide and MDA were significantly increased
in HUVECs subjected to TNF-𝛼 stimulation as compared
to control group, which were prevented by the treatment of
propofol or CGP53353. Addition of nitroglycerine further
promoted the production of superoxide andMDA,whichwas
neutralized by propofol treatment but reversed by CGP53353
treatment.
3.4. NO
𝑥
and Nitrotyrosine Production. We next determined
the production of NOx and nitrotyrosine in HUVECs. Stim-
ulation of TNF-𝛼 increased the levels of NOx and nitroty-
rosine production, and nitroglycerine further increased their
levels (Figure 4). Propofol treatment had no effects on NOx
production in the cells subjected to TNF-𝛼 or combination
with nitroglycerine stimulation, but significantly decreased
TNF-𝛼 induced production of nitrotyrosine. By contrast,
CGP53353 prevented TNF-𝛼 induced NOx production and
nitroglycerine-mediated increase of NOx production and
6 Oxidative Medicine and Cellular Longevity
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Figure 5: Effects of TNF-𝛼, nitroglycerine, and CGP53353 on the protein expression of p-PKC-𝛽
2
(a) and gP91phox (b). Primary cultured
human umbilical vein endothelial cells (HUVECs) were either not treated (control, Con.) or treated with TNF-𝛼 (40 ng/mL) alone (T) or with
TNF-𝛼 in the presence of nitroglycerine (10 𝜇M) (T + N), propofol (100𝜇M) (T + P), CGP53353 (1 𝜇M) (T + C), propofol plus nitroglycerin
(T + N + P), or CGP53353 plus nitroglycerine (T + N + C), respectively, for 24 h. All results are expressed as mean ± S.E.M., 𝑛 = 7, ∗𝑃 < 0.05
compared with Con., T + N, T + P, T + C and T + N + C, 𝑃 < 0.01 compared with Con., T + P, T + C and T + N + C.
reversedTNF-𝛼 induced production of nitrotyrosinewhether
or not in the presence of nitroglycerine.
3.5. Protein Expression of p-PKC-𝛽
2
and gP91phox. We pre-
viously found that PKC-𝛽
2
activation played a critical role
in TNF-𝛼 induced oxidative stress in endothelial cells [27],
and further study have shown that gP91phox but not p22phox
played an important role in TNF-𝛼 induced ROS production
and HUVECs apoptosis [15]. Therefore, our present study
measured the protein expression of p-PKC-𝛽
2
and gP91phox,
one of the membrane subunits of NADPH oxidase, which
catalyzes the generation of superoxide and is the major
source of ROS in cardiovascular system [28]. As shown in
Figure 5, the protein expressions of p-PKC-𝛽
2
and gP91phox
were significantly increased in HUVECs subjected to TNF-
𝛼 stimulation as compared to those of control group, which
were prevented by the treatment of propofol or CGP53353.
Addition of nitroglycerine further increased the protein
expression of p-PKC-𝛽
2
and gP91phox, which was neu-
tralized by propofol treatment but reversed by CGP53353
treatment.
4. Discussion
In the present study, we examined the protective effects of
propofol against TNF-𝛼 induced toxicity in human umbil-
ical vein endothelial cells in the presence or absence of
nitrate tolerance. We demonstrated that propofol inhib-
ited or prevented the adverse effects of TNF-𝛼 stimulation
in the cultured endothelial cells. Furthermore, our results
demonstrated that chronic treatment with nitroglycerine fur-
ther exacerbated TNF-𝛼 induced cell toxicity by promoting
PKC-𝛽
2
activation, with subsequently increased activation of
NADPH oxidase, and ultimately neutralized the protective
effects of propofol. This is the first study showing the role of
PKC-𝛽
2
activation in nitroglycerin induced nitrate tolerance,
which compromises the protective effects of propofol in
endothelial cells subjected to TNF-𝛼 stimulation.
Endothelial dysfunction is implicated in a variety of car-
diovascular diseases, such as hypercholesterolemia, athero-
sclerosis, hypertension, diabetes, and heart failure (see for
review [29]). A relationship has been suggested to exist
between inflammation and endothelial dysfunction [30].
TNF-𝛼, one of the most important proinflammatory cytoki-
nes, is well known to increase ROS production in the endo-
thelium and subsequently induce endothelial dysfunction
[31]. This is well demonstrated by our present study showing
that TNF-𝛼 resulted in a significant increase of LDH release
and cell apoptosis, accompanied with increased superoxide
andNOx production, elevated levels of the lipid peroxidation
product MDA, and increased production of nitrotyrosine, a
nitration product formed by peroxynitrite-mediated nitra-
tion of protein tyrosine residues. All these changes except
NOx production were suppressed or prevented by propo-
fol, an anesthetic with demonstrated antioxidant properties
[9]. However, the precise mechanisms by which propofol
attenuates TNF-𝛼 induced oxidative stress and endothelial
dysfunction are not clear.
Endothelial NADPH oxidase is a major source of supero-
xide in blood vessels and is implicated in the oxidative stress
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accompanying various vascular diseases [32, 33]. NADPH
oxidase contains two membrane-bound subunits gp91phox
(Nox2) and p22phox and cytoplasmic subunits such as
p47phox, p67phox, and a low-molecular-weight G protein
(rac 1 and rac 2) [34]. Many protein kinase pathways have
been involved in the regulation of NADPH oxidase activa-
tion, among which the PKC family seems to play an impo-
rtant role in this process [35]. PKC-𝛽 activation has been
shown to play important or critical roles in NADPH oxidase
activation [36, 37]. PKC-𝛽
2
is preferably upregulated in failing
human hearts [38], which is accompanied with increased
levels of TNF-𝛼 production [39] and NADPH oxidase activa-
tion [40]. Therefore, PKC-𝛽
2
and NADPH oxidase interplay
may play critical roles in mediating cellular damage in
situations associated with increased TNF-𝛼 production, such
as AMI, heart failure, and diabetes, as well as during car-
diac surgery using cardiopulmonary bypass. In the present
study, propofol prevented TNF-𝛼 induced overexpression of
p-PKC-𝛽
2
and gP91phox in endothelial cells. Of interest,
the selective inhibitor of PKC-𝛽
2
CGP53353 has the similar
effects as propofol. Therefore, we assumed that propofol
preserves endothelial cells though inhibits PKC-𝛽
2
activation
signal pathway, including inhibition of NADPH oxidase.
Although there are reports on PKC involvement upon
NADPH oxidase activation after TNF-𝛼 stimulation in cul-
tured HUVECs [8], especially in nitrate tolerance condition,
the major or specific PKC isoform that is involved and the
precise regulation mechanism remain unknown. Our pre-
vious study has demonstrated that PKC-𝛽
2
but not PKC-𝛿
isoformpathway activation played dominant role inROSpro-
duction in this context [15]. However, a new finding in the
present study showed that PKC-𝛽
2
activation was involved
in NADPH oxidase activation in the condition of nitrate
tolerance, a well known phenomenon that the clinical or
hemodynamic response to organic nitrates (such as nitroglyc-
erin, L-arginine) is attenuated or abolished after prolonged,
continuous, or high dose nitrate treatment (see for review
[2]). In the present study, supplementation of nitroglycerine
further increased the apoptosis of endothelial cells and
the activation of PKC-𝛽
2
induced by TNF-𝛼 stimulation,
accompanied with enhanced levels of gP91phox and ROS
production, whichwere reversed by the selective inhibition of
PKC-𝛽
2
with CGP53353. This suggests that excessive activa-
tion of PKC-𝛽
2
and subsequent activation ofNADPHoxidase
paly a critical role in nitrate tolerance induced adverse effe-
cts. Of interest, propofol treatment reversed the increased
levels of superoxide, MDA, nitrotyrosine, and the elevated
protein expression of PKC-𝛽
2
and gP91phox, as well as LDH
release and cell apoptosis in the endothelial cells after TNF-𝛼
stimulation. In the presence of nitroglycerine administration,
however, propofol attenuated but not completely prevented
these changes induced by TNF-𝛼 stimulation. This means
that chronic treatment with nitroglycerin neutralized the
protective effects of propofol.
In summary, the results from the present study indicate
that nitrate tolerance further exacerbated TNF-𝛼 induced
human vascular endothelial cell injury, as well as increased
ROSproduction byPKC-𝛽
2
dependent activation of endothe-
lial NADPH oxidase, and that the protective effects of
propofol were compromised by nitroglycerine administra-
tion in experimental settings that are associated with per-
sistent TNF-𝛼 stimulation. Further studies need to be per-
formed in endothelial cell with deficit of the targeted kinase
enzyme derived fromgene knockout animals or gene silenced
with specific antisenses to confirm the findings of the current
study.
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